Letrozol Omet Pharma

Letrozole, the active ingredient in Letrozol Omet Pharma, is an aromatase inhibitor presented as an oral tablet for oral use. By selectively blocking the aromatase enzyme, it lowers peripheral conversion of androgens to estrogens, thereby decreasing circulating estrogen levels. It is indicated for the management of hormone receptor‑positive breast cancer in postmenopausal women.

GNH USA supplies Letrozol Omet Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide, adhering to EU quality standards and regulatory requirements.

Letrozole is used in the hormonal therapy pathway for estrogen‑dependent breast cancer. - Hormone receptor‑positive early‑stage breast cancer: reduces risk of recurrence after surgery. - Hormone receptor‑positive metastatic breast cancer: slows disease progression in postmenopausal patients. - Adjuvant treatment of postmenopausal breast cancer: improves disease‑free survival when given after primary therapy.

Letrozole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes: sudden warmth and sweating. - Joint and muscle pain: arthralgia and myalgia. - Fatigue: persistent tiredness. - Nausea: mild to moderate upset stomach.

Serious or Rare Side Effects: - Severe liver injury: jaundice or marked enzyme rise. - Bone fracture: due to reduced bone density. - Pulmonary embolism: sudden breathlessness and chest pain. - Allergic reaction: rash, angioedema, or anaphylaxis.

Before initiating therapy, several safety considerations should be reviewed. - Bone health monitoring: assess bone mineral density regularly. - Liver function testing: check hepatic enzymes before and during therapy. - Cardiovascular risk assessment: evaluate history of thrombosis or heart disease. - Hypersensitivity screening: discontinue if signs of allergic reaction appear. - Pregnancy avoidance: drug is contraindicated in pregnancy; ensure effective contraception. - Store at below 25°C: keep in original packaging, protect from moisture and light.

Letrozole can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce letrozole exposure. - Estrogen‑containing hormonal therapy (e.g., hormone replacement therapy): antagonizes therapeutic effect. - Concurrent use with tamoxifen: may diminish efficacy of both agents.

Moderate Interactions (Monitor Closely): - Anticoagulants such as warfarin: letrozole may alter INR, requiring closer monitoring. - Selective serotonin reuptake inhibitors (e.g., fluoxetine): potential for modest pharmacokinetic changes. - Statins (e.g., simvastatin): may increase risk of muscle toxicity.